<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992026</url>
  </required_header>
  <id_info>
    <org_study_id>IUNU-PC-108</org_study_id>
    <nct_id>NCT04992026</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer</brief_title>
  <official_title>A Randomized, Controlled, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Changzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Nantong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Subei people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, controlled, multi-center clinical trial aims to evaluate the efficacy and&#xD;
      safety of prostatectomy for castration-Naive oligometastatic prostate cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to PSA progression progression</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PSA progression is defined as elevated PSA levels(≥2ng/ml) for no less than 2 measurements at least 1 week apart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Radiographic progression</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Radiographic progression is defined as newly discovered soft tissue metastasis according to the RECIST 1.1 or at least 2 bone lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rPFS (radiographic progression free survival)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The time of radiographic progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to castration resistance</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The time to castration resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA remission (≥50%) and time to PSA remission (≥90%)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time to the point when PSA drop to below 50% initial PSA level. Time to the point when PSA drop to below 10% initial PSA level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to new anti-cancer treatment</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time to the point when onther anti-cancer treatment is necessary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Prostatectomy</condition>
  <condition>Oligometastatic Prostate Cancer</condition>
  <condition>Abiraterone</condition>
  <arm_group>
    <arm_group_label>ADT plus abiraterone + surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 6 cycles of first-line treatment (Androgen deprivation therapy + abiraterone acetate along with prednisone) , patients will receive robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection (ePLND) within 9 months of being diagnosed. The ADT+abiraterone treatment will be maintained after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT plus abiraterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be only treated with Androgen deprivation therapy + abiraterone acetate along with prednisone. Prostatectomy won't be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection</intervention_name>
    <description>Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.</description>
    <arm_group_label>ADT plus abiraterone + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.Abiraterone Acetate Tablets</intervention_name>
    <description>1000mg(4 tablets, 250mg per tablet) daily for 6 cycles</description>
    <arm_group_label>ADT plus abiraterone</arm_group_label>
    <arm_group_label>ADT plus abiraterone + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone Acetate Tablets</intervention_name>
    <description>5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets</description>
    <arm_group_label>ADT plus abiraterone</arm_group_label>
    <arm_group_label>ADT plus abiraterone + surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥ 40 and ≤75 years of age.&#xD;
&#xD;
          -  All patients must have a histologically or cytologically diagnosis of prostate cancer.&#xD;
&#xD;
          -  All patients must have been diagnosed oligometastatic prostate cancer which meet the&#xD;
             following criteria. (1) ≤5 metastatic lesions are found by imaging examination (2)No&#xD;
             visceral metastasis was found (3) The diameter of a single lesion ≤5cm or the surface&#xD;
             area ≤250cm2.&#xD;
&#xD;
          -  Patients previously treated with surgical castration or androgen deprivation therapy&#xD;
             must maintain a testosterone level of &lt;50ng/dl or &lt;1.7nmol/L during treatment. Also&#xD;
             the treatment duration should be less than 9 months. Patients were previously treated&#xD;
             with at least 6 cycles of abiraterone.&#xD;
&#xD;
          -  PSA&lt;2ng/ml before enrollment.&#xD;
&#xD;
          -  There was no PSA progression or radiographic progression during previous treatment.&#xD;
&#xD;
          -  Primary lesion must be eligible for radical prostatectomy based on random radiographic&#xD;
             assessment. ( Preoperative clinical staging &lt;T4 or achievable complete resection&#xD;
             agreed by experienced surgeons is deemed as eligible for radical prostatectomy)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 1.&#xD;
&#xD;
          -  Patients must have adequate hematologic function, within 28 days prior to registration&#xD;
             as evidenced by: white blood cell (WBC) ≥ 4.0 × 109 /L, platelets≥ 100 × 109 / L,&#xD;
             hemoglobin ≥ 9g / dL, and international normalized ratio (INR) &lt; 1.5.&#xD;
&#xD;
          -  Patients must have adequate hepatic function, within 28 days prior to registration, as&#xD;
             evidenced by: total bilirubin (TBIL)≤1.5 x upper limit of normal (ULN),and SGOT (AST)&#xD;
             and SGPT (ALT) ≤ 2.5 x ULN.&#xD;
&#xD;
          -  Patients must have adequate renal function, within 28 days prior toregistration, as&#xD;
             evidenced by serum creatinine ≤2×ULN&#xD;
&#xD;
          -  Patients must participate voluntarily and sign an informed consent form(ICF),&#xD;
             indicating that they understand the purpose and required procedures of the study, and&#xD;
             are willing to participate in. Patients must be willing to obey the prohibitions and&#xD;
             restrictions specified in the research protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with neuroendocrine, small cell, or signet ring cell histological features&#xD;
             are not eligible.&#xD;
&#xD;
          -  Patients with visceral metastasis or more than 5 metastatic lesions are excluded.&#xD;
&#xD;
          -  Patients were diagnosed metastatic castration-naive prostate cancer for more than 9&#xD;
             months or showed biochemical or radiographic progression before enrollment.&#xD;
&#xD;
          -  Patients with unresectable primary lesion before enrollment based on CT/MRI.&#xD;
&#xD;
          -  Patients received local treatments such as pre-focal treatment, radiotherapy and&#xD;
             palliative endoscopic resection.&#xD;
&#xD;
          -  Patients with severe or uncontrolled concurrent infections are not eligible.&#xD;
&#xD;
          -  Patients must not have New York Heart Association Class III or IV congestive heart&#xD;
             failure at the time of screening. Patients must not have any thromboembolic event,&#xD;
             unstable angina pectoris, myocardial infarction within 6 months prior to registration.&#xD;
&#xD;
          -  Patients must not have uncontrolled severe hypertension, persistent uncontrolled&#xD;
             diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection.&#xD;
&#xD;
          -  Patients must not have had other malignancies other than prostate cancer in the past 5&#xD;
             years, but cured basal cell or squamous cell skin cancers can be enrolled.&#xD;
&#xD;
          -  Patients with mental illness, mental disability or inability to give informed consent&#xD;
             are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongqian Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Drum Tower Hospital, affiliated to medical school of Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junlong Zhuang, PhD</last_name>
    <phone>+86 15950451917</phone>
    <email>zhuangjl-2008@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongqian Guo, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junlong Zhuang, PhD</last_name>
      <phone>+86 15950451917</phone>
      <email>zhuangjl-2008@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Hongqian Guo</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

